Michael Miller

发表

Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.

A. Howard, R. Nargund, W. Hagmann, 2019, Bioorganic & medicinal chemistry letters.

Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs.

A. Howard, D. Tatosian, R. Orr, 2018, ACS medicinal chemistry letters.

Design and Synthesis of Novel, Selective GPR40 AgoPAMs.

A. Howard, R. Nargund, W. Hagmann, 2017, ACS medicinal chemistry letters.

Discovery of TDI-10229: A Potent and Orally Bioavailable Inhibitor of Soluble Adenylyl Cyclase (sAC, ADCY10).

M. Foley, M. Fushimi, N. Liverton, 2021, ACS medicinal chemistry letters.

Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.

V. Hornak, A. Woods, A. Stamford, 2015, ACS medicinal chemistry letters.

Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

R. Lutz, Rajeeva Singh, Hongsheng Xie, 2011, Bioconjugate chemistry.

Inhibition of 3-phosphoglycerate dehydrogenase (PHGDH) by indole amides abrogates de novo serine synthesis in cancer cells.

L. Cantley, A. Stamford, S. Kargman, 2019, Bioorganic & medicinal chemistry letters.

Discovery of phenyl acetamides as potent and selective GPR119 agonists.

V. Hornak, A. Woods, A. Stamford, 2017, Bioorganic & Medicinal Chemistry Letters.

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Lynn A. Hyde, Z. Yin, M. Kennedy, 2015, The Journal of Pharmacology and Experimental Therapeutics.

The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.

Ping Chen, W. Greenlee, A. Stamford, 2014, Journal of medicinal chemistry.

Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression

T. Tuschl, D. Patel, A. Stamford, 2019, Nature Communications.

Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression

T. Tuschl, D. Patel, A. Stamford, 2019, Nature Communications.

Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates.

M. Fushimi, N. Liverton, S. Kargman, 2022, Journal of medicinal chemistry.

Scaffold Hopping and Optimization of Small Molecule Soluble Adenyl Cyclase Inhibitors Led by Free Energy Perturbation

M. Fushimi, N. Liverton, S. Kargman, 2023, J. Chem. Inf. Model..

Characterization of Pyrrolidinyl-hexahydro-pyranopiperazines as a Novel Kappa Opioid Receptor Agonist Scaffold

J. Vacca, M. Michino, E. Butelman, 2022, ACS chemical neuroscience.

Design and Synthesis of Novel, Selective GPR40 AgoPAMs.

A. Howard, R. Nargund, W. Hagmann, 2017, ACS Medicinal Chemistry Letters.